Molecular epidemiology of Mycobacterium tuberculosis in Ecuador: Recent advances and future challenges

Bernardo Castro-Rodriguez , Greta Franco-Sotomayor , Solón Alberto Orlando , Miguel Ángel Garcia-Bereguiain
{"title":"Molecular epidemiology of Mycobacterium tuberculosis in Ecuador: Recent advances and future challenges","authors":"Bernardo Castro-Rodriguez ,&nbsp;Greta Franco-Sotomayor ,&nbsp;Solón Alberto Orlando ,&nbsp;Miguel Ángel Garcia-Bereguiain","doi":"10.1016/j.jctube.2024.100465","DOIUrl":null,"url":null,"abstract":"<div><p>Tuberculosis (TB) is one of the three leading causes of death from a single infectious agent, <em>Mycobacterium tuberculosis</em> (MTB), together with COVID-19 and HIV/AIDS. This disease places a heavy burden on countries with low socio-economic development and aggravates existing inequalities. For the year 2021, estimations for Ecuador were 8500 TB cases, of which 370 were associated to multiple drug resistance (TB-MDR), and 1160 deaths. In the same year, Ecuador notified 5973 total cases, 401 of them were TB-MDR, pointing out an under diagnosis problem. The few molecular epidemiology studies available conclude that L4 is the most prevalent MTB lineage in Ecuador (with LAM as the main L4 sublineage), but L2-Beijing family is also present at low prevalence. Nevertheless, with less than 1 % MTB isolates genetically characterized by either MIRU-VNTR, spolygotyping or WGS to date, molecular epidemiology research must me improved to assist the TB surveillance and control program in Ecuador.</p></div>","PeriodicalId":37942,"journal":{"name":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","volume":"37 ","pages":"Article 100465"},"PeriodicalIF":1.9000,"publicationDate":"2024-07-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2405579424000524/pdfft?md5=523e158b4dc2231d00ccc23469b658a7&pid=1-s2.0-S2405579424000524-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405579424000524","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

Tuberculosis (TB) is one of the three leading causes of death from a single infectious agent, Mycobacterium tuberculosis (MTB), together with COVID-19 and HIV/AIDS. This disease places a heavy burden on countries with low socio-economic development and aggravates existing inequalities. For the year 2021, estimations for Ecuador were 8500 TB cases, of which 370 were associated to multiple drug resistance (TB-MDR), and 1160 deaths. In the same year, Ecuador notified 5973 total cases, 401 of them were TB-MDR, pointing out an under diagnosis problem. The few molecular epidemiology studies available conclude that L4 is the most prevalent MTB lineage in Ecuador (with LAM as the main L4 sublineage), but L2-Beijing family is also present at low prevalence. Nevertheless, with less than 1 % MTB isolates genetically characterized by either MIRU-VNTR, spolygotyping or WGS to date, molecular epidemiology research must me improved to assist the TB surveillance and control program in Ecuador.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
厄瓜多尔结核分枝杆菌分子流行病学:最新进展与未来挑战
结核病(TB)与 COVID-19 和艾滋病毒/艾滋病(HIV/AIDS)一起,是单一传染源--结核分枝杆菌(MTB)--造成死亡的三大主要原因之一。这种疾病给社会经济发展水平较低的国家带来沉重负担,并加剧了现有的不平等现象。据估计,2021 年厄瓜多尔将出现 8500 例肺结核病例,其中 370 例与多重耐药性(TB-MDR)有关,死亡人数为 1160 人。同年,厄瓜多尔共通报了5973例病例,其中401例为TB-MDR,这表明存在诊断不足的问题。现有的几项分子流行病学研究得出结论,L4 是厄瓜多尔最流行的 MTB 株系(LAM 是主要的 L4 亚株系),但 L2-北京株系的流行率也较低。尽管如此,到目前为止,通过 MIRU-VNTR、spolygotyping 或 WGS 鉴定的 MTB 分离物基因特征还不到 1%,因此必须改进分子流行病学研究,以协助厄瓜多尔的结核病监测和控制计划。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases Medicine-Pulmonary and Respiratory Medicine
CiteScore
4.00
自引率
5.00%
发文量
44
审稿时长
30 weeks
期刊介绍: Journal of Clinical Tuberculosis and Mycobacterial Diseases aims to provide a forum for clinically relevant articles on all aspects of tuberculosis and other mycobacterial infections, including (but not limited to) epidemiology, clinical investigation, transmission, diagnosis, treatment, drug-resistance and public policy, and encourages the submission of clinical studies, thematic reviews and case reports. Journal of Clinical Tuberculosis and Mycobacterial Diseases is an Open Access publication.
期刊最新文献
Determining the relationship between stigmatization and social support in tuberculosis patients Culturing stool specimens has no added value in diagnosing pulmonary tuberculosis Treatment success and mortality among people with multi-drug resistant and rifampicin resistant-tuberculosis on bedaquiline-based regimen at three referral hospitals in Uganda: A retrospective analysis Dissecting regional variability in Pyrazinamide prescribing practices for tuberculosis treatment in Japan Efficacy of nutritional support in combination with standard Buruli ulcer treatment: A case study in Côte d’Ivoire
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1